Actavis rescues Allergan with $66 billion deal
Deal ends takeover fight with Valeant – but Actavis must still be ‘fairly ruthless’ to justify the high price
Deal ends takeover fight with Valeant – but Actavis must still be ‘fairly ruthless’ to justify the high price